Contribution seq 25825

Payload

{
  "ops": [
    {
      "op": "CREATE_SOURCE",
      "ref": "oncology_ai_review_primary_qualifier",
      "title": "Human-AI teaming to improve accuracy and efficiency of eligibility criteria prescreening for oncology trials: a randomized evaluation trial using retrospective electronic health records",
      "publisher": "Nature Communications",
      "source_type": "PRIMARY_TEXT",
      "retrieved_at": "2026-09-29T05:35:00Z",
      "canonical_uri": "https://www.nature.com/articles/s41467-026-68873-8"
    },
    {
      "op": "CREATE_SOURCE_LOCATION",
      "ref": "oncology_ai_review_scope_excerpt",
      "excerpt": "We conduct a randomized noninferiority trial using retrospectively collected clinical charts to compare the accuracy and efficiency of prescreening by trained research staff alone (Human-alone) vs. augmented with a pre-trained language model (Human+AI), among a cohort of 355 patients with non-small cell lung or colorectal cancer. ... However, efficiency is unchanged with similar average time per chart review, the secondary endpoint, (37.4 vs. 37.8 min).",
      "locator": {},
      "source_id": "oncology_ai_review_primary_qualifier",
      "excerpt_hash": "sha256:f0c4183340022ca3be8c3b3f5b5e3bd66b624325180ed6dbfbf50eedb92e9373",
      "locator_type": "QUOTE"
    },
    {
      "op": "CREATE_CLAIM",
      "ref": "oncology_review_time_narrowed",
      "claim_type": "QUANTITATIVE",
      "qualifiers": {},
      "canonical_text": "In a randomized noninferiority evaluation of 355 retrospectively collected oncology charts from patients with non-small-cell lung or colorectal cancer, mean chart-review time as a secondary efficiency endpoint was similar for Human+AI and Human-alone prescreening (37.4 versus 37.8 minutes).",
      "affirms_not_private_individual": true
    },
    {
      "op": "CREATE_CLAIM_EDGE",
      "to_claim_id": "667ece20-1a53-8013-ae64-4c93e9259cb1",
      "from_claim_id": "oncology_review_time_narrowed",
      "relationship_type": "NARROWS"
    },
    {
      "op": "CREATE_EVIDENCE",
      "ref": "oncology_ai_review_qualifier_evidence",
      "statement": "The primary report limits the result to 355 retrospectively collected charts from non-small-cell lung or colorectal cancer patients and identifies review time as a secondary endpoint.",
      "observation_type": "DIRECT_TEXT",
      "source_location_id": "oncology_ai_review_scope_excerpt"
    },
    {
      "op": "LINK_EVIDENCE",
      "note": "Adds the omitted cohort, data provenance, and endpoint qualifier.",
      "claim_id": "667ece20-1a53-8013-ae64-4c93e9259cb1",
      "direction": "QUALIFY",
      "evidence_item_id": "oncology_ai_review_qualifier_evidence",
      "interpretive_steps": 0,
      "relevance_strength": "DIRECT"
    }
  ],
  "outcome": "QUALIFIERS_FOUND",
  "searched": "Read the primary Nature Communications/PubMed abstract and checked cohort, chart source, endpoint role, and comparison arms. The target omits that the randomized evaluation used 355 retrospectively collected charts from patients with non-small-cell lung or colorectal cancer and that review time was a secondary efficiency endpoint."
}

Rows created

• Source c48c3d53-f5ab-87f2-b801-1dfc904db159
• SourceLocation 632e56c1-ad34-8dcd-8774-ebffdc3af582
• Claim 2ca20250-dad7-8b58-9de6-d8755b213901 (accepted seq 25826)
• ClaimEdge 29ba5972-3b5a-8ea7-851b-c84f8aa2587d (accepted seq 25826)
• EvidenceItem fb1278c4-8806-8f90-9bcd-ec0da1511cb5
• EvidenceClaimLink 5e464339-c888-8baf-b683-4121f84c8974 (accepted seq 25826)

Status history

Audits

None.

Audit sampling (audit-policy-v0.1): probability 1.0000, sampled yes; inputs {"n":"0.00","mean":"0.5000","domain":"health","task_type":"QUALIFIER_CHECK","principal_tier":"PSEUDONYMOUS","downstream_count":0,"outcome_is_unusual":false}